Emtricitabine/tenofovir disoproxil fumarate: In combination with a protease inhibitor in HIV-1 infection

Drugs

Volumn 69, Issue 7, 2009, Pages 843-857

  Perry, Caroline M ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ADEFOVIR DIPIVOXIL; AMPRENAVIR PHOSPHATE; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; FAMCICLOVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; RITONAVIR PLUS SAQUINAVIR; SAQUINAVIR; STAVUDINE; TACROLIMUS; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ACUTE KIDNEY TUBULE NECROSIS; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CREATININE CLEARANCE; CROSS RESISTANCE; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOOD DRUG INTERACTION; FOOD INTAKE; GLOMERULUS FILTRATION RATE; GROUPS BY AGE; GROUPS BY SEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KIDNEY INJURY; LIPID DIET; MALAISE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NAUSEA AND VOMITING; PATIENT COMPLIANCE; PLASMA HALF LIFE; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT FAILURE; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; URINARY EXCRETION; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE; VOMITING;

ADENINE; ANTI-HIV AGENTS; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; PHOSPHONIC ACIDS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 66149100884     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200969070-00005     Document Type: Article

References (39)

1. Department of Health and Human Services. Panel on An- tiretroviral Guidelines for Adults and Adolescents: guide- lines for the use of antiretroviral agents in HIV-1 infected adults and adolescents [online]. Available from URL: http://aidsinfo.nih.gov [Accessed 2008 Nov 10]
2. Hammer SM, Eron Jr JJ, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA Panel. JAMA 2008 Aug 6; 300 (5): 555-70
3. Dando TM,Wagstaff AJ. Emtricitabine/tenofovir disoproxil fumarate. Drugs 2004; 64 (18): 2075-82; discussion 2083-4
4. Chapman T, McGavin J, Noble S. Tenofovir disoproxil fumarate. Drugs 2003; 63 (15): 1597-608
5. Frampton JE, Perry CM. Emtricitabine: a review of its use in the management of HIV infection. Drugs 2005; 65 (10): 1427-48
6. Gilead Sciences Inc. Truvada (emtricitabine/tenofovir dis- oproxil fumarate) tablets [online]. Available from URL: http://www.truvada.com/fpi.pdf [Accessed 2009 May 4]
7. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fu- marate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 2004; 43 (9): 595-612
8. Stevens RC, Blum MR, Rousseau FS, et al. Intracellular pharmacology of emtricitabine and tenofovir [letter]. Clin Infect Dis 2004 Sep 15; 39 (6): 877-8; author reply 878-9
9. Borroto-EsodaK,Vela JE,Myrick F, et al. In vitro evaluation of the anti-HIV activity and metabolic interactions of teno- fovir and emtricitabine. Antivir Ther 2006; 11 (3): 377-84
10. Venhoff N, Setzer B, Melkaoui K, et al. Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse tran- scriptase inhibitors. Antivir Ther 2007; 12 (7): 1075-85
11. Gianotti N, Lazzarin A. Sequencing antiretroviral drugs for long-lasting suppression of HIV replication. New Micro- biol 2005 Oct; 28 (4): 281-97
12. Margot NA, Waters JM, Miller MD. In vitro human immuno- deficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine. Antimicrob Agents Chemother 2006 Dec; 50 (12): 4087-95
13. Metzner K, Walter H, Rauch P, et al. The prevalence of drug-resistant virus as a minority quasispecies before in- itiating ART is not associated with therapy failure in per- sons initiating therapy with Truvada plus PI/r or NNRTI [abstract no. 879]. 15th Conference on Retroviruses and Opportunistic Infections; 2008 Feb 3-6; Boston (MA)
14. Elion R, Cohen C, Ward D, et al. Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naive patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine gi- ven once daily. HIV Clin Trials 2008; 9 (4): 213-24
15. Lataillade M, Molina J-M, Thiry A, et al. The CASTLE study 48 week results: the impact of HIV subtypes and baseline resistance on treatment outcomes and the emer- gence of resistance. [abstract no. 123]. XVIIth International HIV Drug Resistance Workshop; 2008 Jun 10-14; Sitges
16. Ortiz R, DeJesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008 Jul 31; 22 (12): 1389-97
17. Johnson MA, Gathe JC, Podzamczer D, et al. A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr 2006 Oct 1; 43 (2): 153-60
18. th Annual Meeting of the Infectious Diseases Society of America; 2008 Oct 12-15; Toronto (ON)
19. Blum MR, Chittick GE, Begley JA, et al. Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers. J Clin Pharmacol 2007 Jun; 47 (6): 751-9
20. Kearney BP, Zong J, Begley J, et al. Bioequivalence of combination tenofovir DF/emtricitabine tablets for one- pill once daily administration [poster no. 7.3]. 5th Inter- national Workshop on Clinical Pharmacology of HIV Therapy; 2004 Apr 1-3; Rome
21. VourvahisM,TappouniH,PattersonK,etal.Thepharmaco- kinetics and viral activity of tenofovir in the male genital tract. J Acquir Immune Defic Synd 2008 Mar 1; 47 (3): 329-33
22. Gilead Sciences International Limited. European Medicines Agency. Emtricitabine/tenofovir disoproxil fumarate (Truvada): summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/truvada [Accessed 2009 May 4]
23. Chittick G, Zong J, Begley J, et al. Pharmacokinetics of emtricitabine/tenofovir disoproxil fumarate and tacrolimus at steady state when administered alone or in combination. Int J Clin Pharmacol Ther 2008 Dec; 46 (12): 627-36
24. Smith K, Fine D, Patel P, et al. Efficacy and safety of abacavir/lamivudine compared to tenofovir/emtricitabine in combination with once-daily lopinavir/ritonavir through 48 weeks in the HEAT Study [abstract no. 774 plus poster]. 15th Conference on Retroviruses and Opportunistic In- fections; 2008 Feb 3-6; Boston (MA)
25. Smith KY, Fine DM, Patel P, et al. Similarity in efficacy and safety of abacavir/lamivudine (ABC/3TC) compared to tenofovir/emtricitabine (TDF/FTC) in combination with QDlopinavir/ritonavir (LPV/r) over 96 weeks in theHEAT study. XVIIth International AIDS Conference; 2008 Aug 3-8; Mexico City
26. Sax P, Tierney C, Collier A, et al. ACTG 5202: Shorter time to virologic failure (VF) with abacavir/lamivudine (ABC/3TC) than tenofovir/emtricitabine (TDF/FTC) as part of combination therapy in treatment-naïve subjects with screening HIV RNA ≥100,000 c/mL [abstract no. THAB0303]. XVII International AIDS Conference; 2008 Aug 3-8; Mexico City
27. Gathe J, daSilva BA, CohenDE, et al. A once-daily lopinavir/ ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks. J Acquir Immune Defic Syndr 2009 Feb 16; 50 (5): 474-81
28. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopina- vir/ritonavir, each in combination with tenofovir and em- tricitabine, for management of antiretroviral-naive HIV-1- infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008 Aug 2; 372 (9639): 646-55
29. Smith KY, Weinberg WG, DeJesus E, et al. Fosamprenavir or atazanavir once daily boosted with ritonavir 100mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT [online]. Avail- able from URL: http://www.aidsrestherapy.com/content/ 5/1/5 [Accessed 2009 Feb 23]
30. Walmsley S, Avihingsanon A, Slim J, et al. Gemini: a non- inferiority study of saquinavir/ritonavir versus lopinavir/ ritonavir as initial HIV-1 therapy in adults. J Acquir Immune Defic Syndr 2009 Apr 1; 50 (4): 367-74
31. Martinez E, Arranz JA, Podzamczer D, et al. Efficacy and safety of NRTI's switch to tenofovir plus emtricitabine (Truvada-) vs. abacavir plus lamivudine (Kivexa-)inpa- tients with virologic suppression receiving a lamivudine containing HAART: the BICOMBO study [abstract no. WESS102 plus oral presentation]. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 2007 Jul 22-25; Sydney (NSW)
32. National Institute of Allergy and Infectious Diseases (NIAID). Efavirenz or atazanavir/ritonavir given with emtricitabine/tenofovir disoproxil fumarate or abaca- vir/lamivudine in HIV infected treatment-naive adults[ClinicalTrials. gov identitfier NCT00118898]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2009 May 1]
33. Hill A, SawyerW. Effects ofNRTI backbone on efficacy of first- line boosted PI based HAART - systemic review of 12 clinical trials in 4896 patients [poster no. H-1254]. 48th ICAAC/IDSA annual meeting; 2008 Oct 25-28; Washington, DC
34. van Lunzen J, Fatkenheuer G, Lutz T, et al. Efficacy and tol- erability of TDF/FTC-containing first line HAART in clinical practice - 48 week data from the German outpatient cohort. 11th European AIDS Conference; 2007 Oct 24; Madrid, 66
35. Mills A, NelsonM, Jayaweera Deal. ARTEMIS: efficacy and safety of darunavir/ritonavir (DRV/r) 800/100mg once-daily vs lopinavir/ritonavir (LPV/r) in treatment-naive, HIV-1-in- fected patients at 96 wks [abstract no. H-1250c plus poster].48th Interscience Conference on Antimicrobial Agents and Chemotherapy and the 46th meeting of the Infectious Dis- eases Society of America; 2008 Oct 25-28;Washington, DC
36. Gilead Sciences Inc. Clinical data on co-administration of emtricitabine/tenofovir disoproxil fumarate and protease in- hibitors. Foster City (CA):Gilead Sciences Inc. (Data on file)
37. th European AIDS Conference; 2007 Oct 24-27; Madrid, 67
38. Yau L. EpzicomQDvs TruvadaQD, both withKaletra QD, in ART-naive patients: the HEAT study 96 weeks analysis results [oral presentation]. XVII International AIDS Con- ference; 2008 Aug 3-8; Mexico City
39. D:A:D Study Group, Sabin CA,Worm SW,Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008 Apr 26; 371 (9622): 1417-26